Roots Analysis

JANUARY 21, 2024

With fourteen approved drugs and several drug candidates being evaluated under different stages of development, antibody drug conjugates (ADCs) are now recognized as a potent class of targeted therapeutics. In this context, the role of the linker molecule and the conjugation technology used is pivotal.

Antibody 40

Antibody Recombinant DNA Technology Drugs Marketing 40

pharmaphorum

AUGUST 28, 2020

An antisense drug developed by GlaxoSmithKline has been shown to suppress the hepatitis B virus (HBV) in a phase 2 trial, raising hopes of a “functional cure” for the widespread disease. Meanwhile, five of 12 previously-untreated patients had 2-log (90%) or a greater reduction in HBV DNA. The drug is in phase 1/2 development.

Drugs 52

Drugs DNA Licensing Licensing 52

Drug Discovery World

JANUARY 19, 2023

The products, tools, talent and licensed technology will enable us to grow our NGS platform and unlock new market opportunities for IDT.” The post Key acquisition for next generation sequencing research assays appeared first on Drug Discovery World (DDW).

Research 52

Research DNA Licensing Licensing 52

Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Research into new cancer drugs remain strong. expressing cancers.

Development 64

Development Research Drugs Antibody 64

pharmaphorum

JUNE 27, 2022

An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a “functional cure” for the widespread disease. The post GSK hepatitis B hope bepirovirsen heads for phase 3 test appeared first on.

DNA 123

DNA Drugs Sales Licensing 123

Drug Discovery World

APRIL 5, 2023

A new, oral, first-in-class experimental cancer drug has shown potent activity against cancer cells and caused shrinkage of hard-to-treat human ovarian tumours grown in mice, a new study shows. It also supports the drug’s potential to treat other cancers. We hope that our drug goes on to show effectiveness in clinical trials.”

Drugs 52

Drugs Scientist Clinical Trials Clinical Trials 52

Drug Discovery World

MAY 5, 2023

The deal also provides Eterna with an exclusive global license to produce an unlimited number of mRNA-engineered natural killer (NK) and T-cell therapies derived from induced pluripotent stem cells (iPSCs). “We The post Eterna acquires Exacis’ allogeneic immuno-oncology platform appeared first on Drug Discovery World (DDW).

Gene Editing 52

Gene Editing Engineer DNA Life Science 52

pharmaphorum

APRIL 7, 2021

In its second licensing deal in the radio-oncology area in consecutive weeks, Novartis has agreed a $1.3 Novartis has made radioligands one of four pillars of its cancer business, along with cell and gene therapy, targeted drugs and immunotherapeutics, and has been steadily bolting on assets to expand its pipeline in this area.

DNA 52

DNA Licensing Licensing Gene Therapy 52

pharmaphorum

NOVEMBER 5, 2021

An oral antiviral drug developed by Pfizer has been shown to dramatically cut the risk of hospitalisation or death from COVID-19 when given in the early stages of infection. When the drug was given within three days of symptom onset, 0.8%

Contract Manufacturing 115

Contract Manufacturing DNA HR Manufacturing 115

Drug Discovery World

OCTOBER 16, 2023

The United Kingdom has established itself as a hub for drug discovery expertise worldwide. There is a range of reasons why this area has become focal point for drug discovery, one of which is the fact that it encompasses the University of Oxford and the University of Cambridge, two of the oldest and most prestigious universities in the world.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

The Pharma Data

MARCH 30, 2021

Targeted radioligand therapy is a type of precision medicine combining two key elements: a targeting compound, or ligand, and a radioactive isotope, causing DNA damage that inhibits tumor growth and replication. These targeted drugs bind to markers or proteins over-expressed by certain tumors, or tumor-associated tissue, such as stroma.

Protein 52

Protein Licensing Licensing Containment 52

pharmaphorum

OCTOBER 3, 2022

The re-evaluation followed a six-year period during which the DMD drug had been available under a managed access agreement (MAA), which ends in January next year, and under which 60 children have had access to Translarna. Translarna was the first licensed treatment for DMD which addresses the loss of dystrophin.

Gene Therapy 98

Gene Therapy Gene FDA Approval DNA 98

pharmaphorum

FEBRUARY 19, 2021

Once someone is infected with HIV it stays with them for life thanks to the retrovirus’s ability to inject its DNA code into the host. The cash will also help develop two other preclinical drugs, EBT-104 for Herpes Simplex Virus and EBT-107 for hepatitis B.

Gene Editing 105

Gene Editing In-Vivo DNA In-Vitro 105

Drug Discovery World

AUGUST 23, 2022

ASTX727 is an orally administered, fixed-dose combination of the approved anti-cancer DNA hypomethylating agent, decitabine, together with cedazuridine, an inhibitor of cytidine deaminase (CDA). . The post Combination treatment for AML closer to approval following EMA nod appeared first on Drug Discovery World (DDW). Abstract P573.

Clinical Trials 52

Clinical Trials Clinical Trials DNA Licensing 52

XTalks

MAY 22, 2023

Related: 5 Food Companies Working With Precision Fermentation Technology How Pairwise Leverages CRISPR Technology CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, is a gene-editing technique that can be used to alter the DNA of cells to enhance certain characteristics or reduce less desirable ones.

Branding 98

Branding Gene Editing DNA Production 98

Pharmaceutical Technology

FEBRUARY 14, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. The most common heteroatoms are nitrogen (N), oxygen (O) and sulphur (S).

Antibody 130

Antibody Hormones DNA Licensing 130

Drug Discovery World

JUNE 5, 2023

It also comprises NEPHROSCANTM, a diagnostic product in partnership with GE Healthcare which is approved by the US Food and Drug Administration (FDA) and affords Ariceum expanded operations in the US. The post Ariceum Therapeutics expands pipeline with acquisition appeared first on Drug Discovery World (DDW).

FDA Approval 52

FDA Approval DNA Production Licensing 52

pharmaphorum

MARCH 8, 2021

AZ is seeking to use Lynparza in patients who had also been previously treated with the chemotherapy drug docetaxel, but NICE has concluded that the application failed to provide evidence of the PARP inhibitor’s value compared to standard therapy.

Hormones 98

Hormones Marketing Trials DNA 98

pharmaphorum

JANUARY 30, 2022

Top of the list was Oxford Nanopore’s stellar debut on the London Stock Exchange at the end of September, raising £350 million and propelling the vale of the DNA sequencing specialist up towards the £5 billion mark. The post Offshore warning as UK biotech investment rises sharply in 2021 appeared first on.

Life Science 98

Life Science Allergies DNA Licensing 98

pharmaphorum

MAY 7, 2021

Founded by Nobel prize winner Emmanuelle Charpentier, CRISPR Therapeutics has been at the forefront of the gene editing technology and has refined it to the point where it can be used to accurately edit DNA to correct genetic conditions or modify cells to fight disease.

Gene Editing 52

Gene Editing Gene Genetic Engineering DNA 52

XTalks

JUNE 20, 2022

Alnylam Pharmaceuticals, a leading RNA interference (RNAi) therapeutics biopharmaceutical company, announced it received approval from the US Food and Drug Administration (FDA) for its RNAi therapeutic Amvuttra (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (ATTR) amyloidosis in adults.

FDA Approval 98

FDA Approval Protein Genetics RNA 98

The Pharma Data

JUNE 7, 2023

LNPs are spheric drug delivery bodies which can be equipped with therapeutic payloads for intracellular delivery. In addition to mRNA, Acuitas LNP can be used to deliver a range of different nucleic acid therapeutics including small interfering RNA (siRNA), antisense oligonucleotides and DNA.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

pharmaphorum

FEBRUARY 5, 2021

DNA testing company 23andMe has signed a deal to merge with a ‘blank cheque’ company set up by Virgin billionaire Sir Richard Branson as a shortcut to a public listing. Meanwhile, the therapeutics platform has been validated by the $300 million collaboration with GlaxoSmithKline on drug discovery signed in 2018, said Lovell.

Genetics 52

Genetics DNA Life Science Clinical Trials 52

pharmaphorum

MAY 24, 2022

Monkeypox is considered less likely to mutate quickly because it is a DNA virus rather than an RNA virus like influenza or COVID-19. ” Vaccines and drugs are available. There’s also a licensed antiviral drug for monkeypox. The US FDA also approved a new intravenous form of the drug last week.

Vaccination 95

Vaccination Vaccine RNA DNA 95

Delveinsight

MARCH 2, 2021

HitGen & UPPTHERA Collaborate for Drug Delivery Research. HitGen has entered into a collaboration for drug discovery research with UPPTHERA to identify small molecule Hits against previous known-to-be undruggable targets and novel E3 ligase. Junshi & AstraZeneca To Commercialize Toripalimab in China.

Drug Delivery 40

Drug Delivery Research Drugs Gene Editing 40

The Pharma Data

DECEMBER 16, 2020

OS is a rigorous endpoint that the FDA has recognized as a basis for approval of oncology drugs when a statistically significant improvement can be shown relative to a randomized control arm. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc.

FDA Approval 52

FDA Approval Drugs Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 21, 2021

In addition, Spectrum also announced an oral presentation on the structural classification of atypical EGFR mutations and their patterns of drug sensitivity. Title: Structural classification of atypical EGFR mutations identifies four major subgroups with distinct patterns of drug sensitivity Speaker: Jacqulyne P.

Clinical Trials 52

Clinical Trials Clinical Trials Licensing Licensing 52

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Its primary focus is on oncology, cardiovascular, immunology, and fibrotic therapeutic projects.

Antibody 130

Antibody DNA Genome Genomics 130

pharmaphorum

OCTOBER 1, 2021

Shares in DNA sequencing specialist Oxford Nanopore rocketed after the company made its debut on the London Stock Exchange yesterday, rising nearly 50% to propel its valuation up towards the £5 billion ($6.7 It may also use the cash injection for “in-licensing opportunities and potential acquisitions”, according to the document.

Marketing 52

Marketing Business Development Genome Genomics 52

Delveinsight

DECEMBER 17, 2020

Following that hypothesis, scientists designed oral inhibitors, which could target mitochondrial DNA (mtDNA). In mice, treatment with the drug led to strong anti-tumour responses, decreasing tumour growth without affecting healthy cells, as per reported in Nature by the team. in 2017.

Gene Therapy 96

Gene Therapy Gene DNA Genetics 96

The Pharma Data

JANUARY 5, 2021

Ribometrix’s technology platform focuses on identify 3D “motifs” in RNA molecules so it can then design small molecule drugs that bind to these motifs to treat diseases. So therapeutics that focus on RNA are designed to stop the DNA from coding for disease-causing proteins.

RNA 52

RNA Protein Bioavailability DNA 52

Drug Discovery World

MARCH 7, 2023

For International Women’s Day, DDW’s Diana Spencer celebrates some of the women in leadership making an impact on the drug discovery and life sciences sector. She has over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing.

Life Science 98

Life Science DNA Clinical Development Development 98

pharmaphorum

SEPTEMBER 8, 2022

It is a similar approach to that of another form of oncology treatment that is also experiencing a surge of interest, antibody-drug conjugates (ADCs). Last year, the company signed two deals in quick succession, which saw it form a licensing deal worth $1.3 The drug was added to Novartis’ portfolio through a $2.1

Manufacturing 105

Manufacturing Development Drugs Antibody 105

pharmaphorum

JULY 5, 2021

Swedish private equity group EQT has swooped on Parexel just two weeks after selling plasmid DNA producer Aldevron – whose technology is used to make the Moderna COVID-19 vaccine – to medical equipment producer Danaher Corp for $9.6

Clinical Trials 63

Clinical Trials Clinical Trials Regulation Trials 63

The Pharma Data

JUNE 28, 2021

The companies acquired by Bayer, Noria and PSMA Therapeutics, have exclusive world-wide rights to technology licensed from Weill Cornell Medicine (New York, NY, USA) and Johns Hopkins University (Baltimore, MD, USA). It has been demonstrated to inflict difficult to repair damage to tumor cells by inducing DNA double strand breaks.

Licensing 52

Licensing Licensing Medicine Development 52

Pfizer

JANUARY 27, 2023

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Sufficient information is not available to assess for a potential drug interaction. Modification of other medications is needed due to a potential drug interaction. AUTHORIZED USE The U.S.

Marketing 75

Marketing Production Drugs Licensing 75

pharmaphorum

DECEMBER 21, 2020

Their technology is based on synthetic messenger RNA – short for ribose nucleic acid – which is a short transcript of a longer DNA code. Its portfolio of products was broad – including a drug being developed with AstraZeneca for cardiovascular diseases, a cancer immunotherapy and a potential Zika vaccine. “I

Vaccination 110

Vaccination Vaccine Doctors Doctor 110